TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
暂无分享,去创建一个
Ken Kato | H. Tachibana | T. Kojima | H. Nishikawa | K. Yamaguchi | N. Fuse | T. Tsushima | H. Hara | H. Bando | M. Wakabayashi | H. Hojo | Y. Togashi | S. Kadowaki | S. Kageyama | D. Kotani | M. Fukutani | M. Nakamura | K. Chin
[1] H. Miyata,et al. Comprehensive registry of esophageal cancer in Japan, 2013 , 2020, Esophagus.
[2] Sung-Bae Kim,et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[3] Y. Tachimori,et al. Comprehensive registry of esophageal cancer in Japan, 2012 , 2019, Esophagus.
[4] R. Fisher,et al. A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer. , 2019, Journal of Clinical Oncology.
[5] Sung-Bae Kim,et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. , 2019, Journal of Clinical Oncology.
[6] D. Planchard,et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.
[7] Manish R. Sharma,et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[9] Joe Y. Chang,et al. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells , 2016, Clinical Cancer Research.
[10] T. Kawano,et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303) , 2015, Cancer science.
[11] Sean S. Park,et al. PD-1 Restrains Radiotherapy-Induced Abscopal Effect , 2015, Cancer Immunology Research.
[12] C. Drake,et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.
[13] I. Stratford,et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.
[14] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[15] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[16] Ping Zhang,et al. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. , 2008, Molecular immunology.
[17] M. Shinoda,et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). , 2004, Japanese journal of clinical oncology.
[18] S. Yoshida,et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.